toxoplasma
gondii
singlecel
oblig
intracellular
protozoan
infect
rate
approxim
worldwid
popul
pregnant
women
parasit
may
threaten
health
even
fatal
concern
congenit
infect
fetus
also
major
opportunist
infect
immunodefici
individu
caus
toxoplasm
enceph
retinochoroid
result
effect
vaccin
gondii
urgent
need
prevent
diseas
variou
vaccin
strategi
toxoplasmosi
rodent
model
use
last
decad
howev
effect
vaccin
remain
challeng
test
vaccin
abl
confer
steril
immun
infect
current
research
gondii
vaccin
focus
antigen
express
tachyzoit
stage
induc
partial
protect
immun
develop
varieti
epitop
combin
differ
stage
life
cycl
includ
tachyzoit
bradyzoit
tissu
cyst
sporozoit
oocyst
like
induc
full
protect
develop
bioinformat
epitop
vaccin
consid
novel
immun
approach
prevent
gondii
infect
addit
appropri
deliveri
system
vaccin
could
increas
transfect
effici
immun
cell
adenoviru
penetr
host
cell
deliv
vaccin
antigen
antigenpres
cell
apc
elicit
vigor
sustain
tcell
respons
promis
gondii
vaccin
vector
use
effect
transport
immunogen
recent
studi
also
found
recombin
canin
adenoviru
express
provid
partial
protect
acut
gondii
infect
mice
indic
adenoviru
vector
may
potenti
use
develop
effect
vaccin
gondii
infect
mucos
immun
system
consist
special
epitheli
cell
trigger
humor
cell
immun
respons
antigen
administ
appropri
adjuv
attenu
live
vaccin
via
mucos
rout
oral
nasal
sublingu
ocular
genit
rectal
furthermor
local
mucos
immun
lead
antigenspecif
bcell
respons
mucos
site
also
system
henc
greater
need
effect
vaccin
exert
protect
effect
mucos
surfac
especi
intracellular
parasit
gondii
research
util
recombin
adenoviru
vaccin
express
ubiquitinconjug
multistag
antigen
segment
aduma
deriv
differ
lifecycl
stage
gondii
evalu
immun
respons
obtain
differ
intramuscular
vaccin
rout
describ
earlier
studi
explor
optim
immun
pathway
recombin
adenoviru
gondii
vaccin
plan
determin
immun
respons
protect
efficaci
vaccin
balbc
mice
via
five
rout
intramuscular
im
intraven
iv
subcutan
sc
intraor
io
intranas
experiment
procedur
anim
use
present
studi
grant
prior
approv
institut
anim
care
use
committe
shandong
univers
contract
human
endpoint
chosen
termin
pain
distress
experiment
anim
via
euthanasia
mice
monitor
daili
week
sign
toxoplasmosi
includ
food
water
intak
difficulti
fatigu
sever
ascit
test
anim
show
sign
ill
euthan
immedi
ga
tissu
cyst
lowvirul
prugniaud
pru
strain
type
ii
tachyzoit
highvirul
rh
strain
type
gondii
kindli
provid
professor
xingquan
zhu
lanzhou
veterinari
research
institut
propag
harvest
describ
previou
studi
use
vivo
challeng
mice
aduma
vaccin
construct
previous
describ
briefli
aduma
construct
use
admax
system
hanbio
shanghai
china
ubiquitinconjug
multistag
antigen
segment
uma
clone
shuttl
plasmid
phbadmcmvgfp
aduma
gener
homolog
recombin
phbadmcmvgfpuma
phbadbhg
cell
aduma
particl
titer
plaqueform
unit
pfu
ml
purifi
cesium
chlorid
gradient
centrifug
store
storag
buffer
mm
tri
mm
sucros
ph
specificpathogenfre
femal
balbc
mice
age
week
purchas
shandong
univers
laboratori
anim
centr
jinan
china
anim
vaccin
includ
intramuscular
intraven
subcutan
intraor
intranas
immun
group
mice
per
group
intramuscular
group
mice
inject
pfu
aduma
quadricep
muscl
intraven
group
mice
inject
pfu
aduma
caudal
vein
subcutan
oral
group
administ
pfu
aduma
subcutan
inject
intragastr
administr
intranas
vaccin
mice
anesthet
isofluran
oxygen
given
nasal
drip
pfu
aduma
head
cant
min
group
also
mice
treat
phosphatebuff
salin
pb
control
mice
vaccin
twice
interv
tabl
summar
treatment
given
mice
figur
show
studi
flowchart
vaccin
mice
serum
sampl
collect
retroorbit
bleed
day
standard
elisa
use
determin
level
gondiispecif
antibodi
igg
iga
serum
sampl
inocul
mice
done
chang
method
previous
describ
briefli
flatbottom
plate
precoat
uma
peptid
pool
concentr
mm
carbonatebicarbon
buffer
ph
overnight
mous
sera
dilut
pb
incub
h
wash
plate
bound
antibodi
react
horseradish
peroxidas
hrp
conjug
goat
antimous
igg
iga
sigmaaldrich
usa
h
peroxidas
activ
reveal
tmb
mgml
stop
ad
optic
densiti
od
nm
measur
thermo
scientif
multiskan
fc
micropl
photomet
thermo
scientif
usa
spleen
remov
three
immun
mice
per
group
four
week
last
immun
singlecel
splenocyt
harvest
follow
method
describ
previou
studi
isol
splenocyt
plate
plate
densiti
per
well
medium
sigmaaldrich
usa
supplement
fetal
calf
serum
cultur
concanavalin
cona
sigmaaldrich
uma
peptid
pool
cell
prolif
activ
measur
accord
manufactur
instruct
dojindo
cell
count
dojindo
japan
result
express
absorb
nm
level
cytokin
product
determin
use
splenocyt
three
mice
per
group
week
last
immun
commerci
elisa
kit
r
system
usa
use
follow
manufactur
instruct
assay
h
h
h
cultur
supernat
obtain
previous
describ
done
collect
cell
supernat
three
well
plate
centrifug
discard
cell
debri
supernat
test
cytokin
detect
replic
three
time
spleen
cell
stain
fluorescein
isothiocyan
fitc
label
antimous
monoclon
antibodi
phycoerythrin
pe
label
antimous
monoclon
antibodi
lymphocyt
subset
measur
beckman
coulter
flow
cytomet
beckman
coulter
usa
four
week
last
immun
mice
challeng
type
type
parasit
evalu
protect
effect
six
mice
per
group
infect
intraperiton
tachyzoit
gondii
rh
strain
type
parasit
last
immun
surviv
time
mice
observ
record
anoth
six
immun
mice
per
group
infect
via
gastric
rout
cyst
gondii
pru
type
parasit
strain
challeng
mice
sacrif
week
later
brain
remov
homogen
ml
pb
mean
number
cyst
per
brain
determin
count
three
sampl
aliquot
homogen
brain
optic
microscop
statist
signific
group
calcul
oneway
analysi
varianc
anova
use
spss
softwar
surviv
rate
compar
kaplanmei
method
pvalu
less
p
consid
signific
assess
system
humor
immun
respons
obtain
five
immun
rout
aduma
collect
sera
differ
time
immun
antit
gondii
igg
igg
subtyp
detect
elisa
shown
figur
level
antibodi
titer
increas
five
aduma
immun
rout
compar
control
level
gondiispecif
igg
antibodi
increas
dramat
sera
vaccin
mice
day
day
achiev
highest
day
p
among
differ
immun
rout
intramuscular
group
achiev
highest
titer
igg
antibodi
subcutan
nasal
oral
group
decreas
order
fig
intraven
vaccin
group
titer
igg
increas
rapidli
week
gradual
slowli
thereaft
make
final
titer
rel
low
evalu
serum
igg
subtyp
antibodi
reveal
gondiispecif
antibodi
level
significantli
increas
five
aduma
vaccin
group
compar
control
p
differ
substanti
valu
antibodi
rel
higher
intramuscular
subcutan
vaccin
group
vaccin
rout
fig
evalu
abil
aduma
induc
local
mucos
immun
respons
via
five
pathway
mucos
iga
antibodi
respons
detect
collect
mous
sera
shown
figur
vaccin
intraor
intranas
group
elicit
strong
gondiispecif
iga
antibodi
level
significantli
higher
vaccin
rout
p
fig
howev
statist
signific
differ
iga
titer
intramuscular
intraven
subcutan
vaccin
group
compar
control
group
p
cellular
immun
respons
first
evalu
analysi
tcell
subset
lymphocyt
subset
immun
mice
assay
flow
cytometri
tabl
show
percentag
tcell
comparison
control
group
percentag
tcell
vaccin
group
aduma
increas
significantli
p
percentag
tcell
mice
immun
intranas
intraor
intramuscularli
higher
mice
immun
subcutan
intranas
rout
p
cellmedi
immun
induc
immun
mice
evalu
measur
amount
cytokin
tabl
show
valu
vaccin
group
highest
level
detect
nasal
immun
group
pgml
pgml
respect
furthermor
lymphocyt
prolifer
abil
also
higher
mice
inocul
nasal
aduma
control
p
howev
statist
signific
differ
amount
immun
group
control
group
p
tabl
evalu
protect
immun
six
mice
group
given
intraperiton
inject
tachyzoit
gondii
rh
strain
week
vaccin
surviv
rate
mice
immun
via
differ
rout
shown
figur
mice
immun
aduma
via
im
io
show
almost
surviv
rate
lower
surviv
rate
found
iv
sc
immun
group
day
challeng
control
mice
die
within
day
level
protect
effect
chronic
infect
evalu
count
cyst
brain
mice
challeng
cyst
pru
strain
gondii
fig
obviou
reduct
burden
brain
cyst
detect
immun
mice
compar
control
mice
p
brain
cyst
number
oral
nasal
immun
group
significantli
reduc
respect
much
lower
immun
group
inject
muscl
via
venou
rout
via
subcutan
rout
p
antigen
deliveri
pathway
key
paramet
induct
protect
immun
respons
vaccin
intracellular
pathogen
novel
inocul
gener
agreement
effect
mucos
vaccin
oral
nasal
sublingu
genit
tract
vaccin
could
dramat
stimul
protect
immun
respons
mucos
infect
also
hiv
mycobacterium
tuberculosi
mani
pathogen
studi
compar
capabl
aduma
induc
system
humor
cellular
immun
respons
local
mucos
immun
respons
via
five
vaccin
pathway
im
iv
sc
io
mucos
vaccin
advantag
compar
system
vaccin
product
regulatori
perspect
previou
studi
reveal
middl
east
respiratori
syndrom
mer
vaccin
greatli
enhanc
local
mucos
immun
respons
immun
balbc
mice
intranas
inocul
method
ideal
attenu
vaccin
could
engin
limit
capac
replic
deliv
effect
antigen
avoid
unwant
inflammatori
respons
recombin
adenovirus
intens
investig
vaccin
carrier
mani
pathogen
infect
ebola
viru
hiv
malaria
parasit
sever
clinic
trial
shown
vaccin
base
adenovirus
could
elicit
vigor
sustain
tcell
respons
advantag
safeti
high
immunogen
result
show
aduma
vaccin
could
effect
improv
humor
respons
intramuscular
pathway
system
humor
igg
antibodi
respons
induc
intraor
intranas
vaccin
pathway
compar
induc
pathway
collect
mous
sera
interestingli
found
igg
antibodi
intraven
vaccin
group
increas
sharpli
first
slowli
later
even
boost
immun
consid
antigen
transmit
bloodstream
directli
induc
strong
immun
respons
earli
stage
also
caus
immun
toler
explain
antibodi
level
increas
slowli
follow
time
moreov
evalu
serum
igg
subtyp
antibodi
respons
reveal
vaccin
pathway
induc
rel
higher
level
studi
note
aduma
induc
slightli
bias
antibodi
respons
known
product
igg
subtyp
driven
cytokin
secret
cellular
immun
respons
therefor
presenc
indirectli
suggest
vaccin
protocol
also
promot
activ
cellmedi
respons
data
suggest
aduma
immun
mucos
vaccin
rout
capabl
elicit
similar
system
humor
antibodi
respons
compar
elicit
intramuscular
pathway
vaccin
mice
mucos
vaccin
toxoplasma
infect
requir
induct
protect
respons
mucos
surfac
also
induct
system
protect
immun
respons
system
compart
first
line
defens
protect
mucou
membran
specif
siga
play
protect
role
mani
pathogen
therefor
vaccin
capabl
induc
strong
local
mucos
immun
repres
secretori
iga
would
help
prevent
gondii
infect
data
indic
gondiispecif
iga
antibodi
respons
vaccin
mous
sera
elicit
io
vaccin
aduma
significantli
higher
induc
vaccin
rout
confirm
abil
aduma
induc
strong
mucos
immun
via
mucos
rout
memori
tcell
consist
tcell
play
vital
role
establish
protect
immun
host
tcell
control
spread
develop
gondii
infect
synergi
tcell
studi
lymphocyt
subset
immun
mice
assay
flow
cytometri
mark
increas
percentag
tcell
mice
immun
aduma
vaccin
via
mucos
rout
cytokin
play
critic
role
activ
th
cell
know
cell
respons
limit
tissu
extens
parasit
product
result
show
contrast
blank
control
high
level
induc
mice
immun
aduma
especi
treat
intraor
intranas
howev
differ
product
vaccin
control
group
addit
splenocyt
prolifer
activ
significantli
enhanc
mice
immun
via
oral
nasal
rout
result
clearli
suggest
mucos
vaccin
aduma
significantli
augment
cellular
immun
respons
lymphocyt
consid
major
effector
respons
control
parasit
infect
secret
cellular
respons
toxoplasmosi
studi
highli
virul
rh
strain
mild
virul
pru
strain
gondii
use
challeng
studi
rh
strain
easi
induc
acut
infect
mice
intraperiton
inject
tachyzoit
pru
strain
like
induc
chronic
infect
mice
follow
intragastr
administr
cyst
order
simul
acut
chronic
infect
host
mice
infect
rh
strain
pru
strain
differ
challeng
rout
challeng
lethal
dose
gondii
five
group
immun
aduma
prolong
surviv
time
compar
control
mice
particular
mice
immun
intranas
intraor
show
higher
surviv
rate
immun
rout
sinc
protect
via
vaccin
strain
parasit
high
mortal
dose
rh
parasit
immun
mice
larger
optim
challeng
dose
determin
futur
furthermor
higher
mucos
immun
respons
induc
intraor
intranas
vaccin
aduma
may
explain
signific
reduct
cyst
burden
mice
immun
aduma
intraor
intranas
exhibit
reduct
brain
cyst
respect
earlier
studi
determin
mortal
cytokin
product
parasit
burden
challeng
infect
suscept
resist
strain
mice
similar
dose
gondii
parasit
studi
found
differ
inbr
strain
mice
markedli
differ
suscept
gondii
infect
suscept
differ
may
due
differ
virul
parasit
differ
genet
makeup
mice
term
immun
respons
studi
one
inbr
strain
mice
use
experi
therefor
necessari
assess
differ
immun
differ
strain
mice
futur
research
summari
mucos
immun
recombin
adenoviru
vaccin
express
ubiquitinconjug
multistag
antigen
segment
aduma
potenti
vaccin
rout
elicit
protect
immun
respons
compar
immun
rout
oral
nasal
immun
aduma
elicit
robust
system
mucos
immun
respons
accompani
signific
increas
surviv
rate
challeng
highli
virul
parasit
dramat
reduct
brain
cyst
burden
vaccin
mice
challeng
mild
strain
gondii
therefor
result
studi
contribut
develop
effect
safe
mucos
vaccin
prevent
gondii
infect
author
declar
compet
interest
